{"nctId":"NCT03521141","briefTitle":"PRecision Interventions for SMoking in the SCCS","startDateStruct":{"date":"2018-05-18","type":"ACTUAL"},"conditions":["Tobacco Use Cessation"],"count":67,"armGroups":[{"label":"Guideline-Based Care (GBC)","type":"OTHER","interventionNames":["Drug: Nicotine patch","Drug: Varenicline","Behavioral: NCI \"Clearing the Air\""]},{"label":"Nicotine Metabolite Ratio (PC-NMR)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nicotine patch","Drug: Varenicline","Genetic: Nicotine metabolism","Behavioral: NCI \"Clearing the Air\""]},{"label":"Respiragene (PC-Respiragene)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nicotine patch","Drug: Varenicline","Genetic: Genetically-informed lung cancer risk score","Behavioral: NCI \"Clearing the Air\""]}],"interventions":[{"name":"Nicotine patch","otherNames":["Nicotine Replacement Therapy"]},{"name":"Varenicline","otherNames":["Chantix"]},{"name":"Nicotine metabolism","otherNames":[]},{"name":"Genetically-informed lung cancer risk score","otherNames":[]},{"name":"NCI \"Clearing the Air\"","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Daily smoker of ≥5 cigarettes per day (CPD)\n* Enrolled participant of the Southern Community Cohort Study (SCCS) who completed a prior survey indicating they were willing to be contacted regarding a smoking cessation clinical trial\n* Residence in Tennessee (TN) or Mississippi (MS)\n* Has stored blood sample with the SCCS\n* Has established primary care provider (PCP)\n* Medically eligible and willing to take varenicline and NRT\n\nExclusion Criteria:\n\n* Currently taking medication to quit smoking\n* enrolled, or planning to be enrolled, in another smoking cessation program\n* Inability to give informed consent or participate due to cognitive disorder (e.g., dementia, severe intellectual disability)\n* Unstable psychiatric illness (ER or hospitalized for psychiatric condition in past 6 months, change in psychiatric medications in past 3 months, or suicidal ideation in past 6 months)\n* not able to send or receive mail\n* no access to a telephone or inability to communicate by telephone\n* unable to speak and read English\n* history of seizures or Buerger's disease\n* currently pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intervention Feasibility: Ability to Retain Participants","description":"Feasibility of delivering precision care (PC) interventions in the Southern Community Cohort Study (SCCS), as evidenced by ability to recruit, engage, and retain participants through end of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Cessation History - Quit Attempts","description":"Participants who reported making a quit attempt during the trial, as defined by use of a quit aid or reporting \"not at all\" for current smoking at any timepoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Cessation History - Medication Use","description":"Participants who received, and those who subsequently used, a smoking cessation medication during the trial","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Cessation History - Quitline","description":"Participants who reported using the quitline (\"phone support\") at any point during the trial","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Cessation History - Self-reported Abstinence","description":"Participants who self-reported abstinence at the 6 month survey","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cessation History - Validated Abstinence","description":"Participants who completed a salivary cotinine sample; participants who biochemically-verified as abstinent (salivary cotinine ≤10ng/ml)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Insomnia and/or other sleep","Agitation and/or Irritability","Depressed mood","Cough","Anger"]}}}